FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The initiative is focused on a problem that continues to plague cancer outcomes in India
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated